Gut Hormones After Oral Versus Intravenous Amino Acids

Normal Non-fluency Clinical Trial

Official title:

Release of Gut Hormones After Oral Versus Intravenous Amino Acids

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01366768
• Other study ID #: 003
• Status: Completed
• Phase: N/A
• First received: May 31, 2011
• Last updated: October 9, 2012
• Start date: May 2011
• Est. completion date: September 2012

Study information

• Verified date: October 2012
• Source: Lund University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: Medical Products Agency
• Study type: Interventional

Clinical Trial Summary

The study hypothesis is that gut hormones are released after oral but not intravenous amino acids which result in stimulation of insulin secretion.

Description:

Amino acid mixture is given orally or intravenously to match total concentrations of amino acids in healthy subjects. Samples are taken regularly for 300 min after administrations. Plasma levels of the gut hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)and determined and related to plasma levels of insulin and glucagon.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: September 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 30 Years

Eligibility

Inclusion Criteria:

• Healthy subjects

Exclusion Criteria:

• Diabetes

• Liver disease

• Kidney disease

• Thyroid disease

Study Design

Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Normal Non-fluency

Intervention

Other:
• Oral amino acid mixture
Amino acid mixture 2,93 ml/kg
• Intravenous amino acid administration
Amino acid mixture 2,93 ml/kg

Locations

Country	Name	City	State
Sweden	Department of Clinical Sciences Lund, Lund University	Lund

Sponsors (1)

Lead Sponsor	Collaborator
Lund University

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gut hormone secretion		300 min	No
Secondary	Insulin secretion		300 min	No